Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Sci Rep. 2017 Jul 6;7(1):4829. doi: 10.1038/s41598-017-05058-w.
Virtual screening offers an efficient alternative to high-throughput screening in the identification of pharmacological tools and lead compounds. Virtual screening is typically based on the matching of target structures or ligand pharmacophores to commercial or in-house compound catalogues. This study provides the first proof-of-concept for our recently reported method where pharmacophores are instead constructed based on the inference of residue-ligand fragments from crystal structures. We demonstrate its unique utility for G protein-coupled receptors, which represent the largest families of human membrane proteins and drug targets. We identified five neutral antagonists and one inverse agonist for the histamine H receptor with potencies of 0.7-8.5 μM in a recombinant receptor cell-based inositol phosphate accumulation assay and validated their activity using a radioligand competition binding assay. H receptor antagonism is of large therapeutic value and our ligands could serve as starting points for further lead optimisation. The six ligands exhibit four chemical scaffolds, whereof three have high novelty in comparison to the known H receptor ligands in the ChEMBL database. The complete pharmacophore fragment library is freely available through the GPCR database, GPCRdb, allowing the successful application herein to be repeated for most of the 285 class A GPCR targets. The method could also easily be adapted to other protein families.
虚拟筛选为药理学工具和先导化合物的识别提供了一种高效的高通量筛选替代方法。虚拟筛选通常基于将靶结构或配体药效团与商业或内部化合物目录相匹配。本研究首次证明了我们最近报道的方法的概念验证,该方法基于从晶体结构推断残基-配体片段来构建药效团。我们展示了它在 G 蛋白偶联受体(GPCR)中的独特用途,GPCR 是人类膜蛋白和药物靶点中最大的家族。我们在基于重组受体细胞的三磷酸肌醇积累测定中鉴定了五种组胺 H 受体的中性拮抗剂和一种反向激动剂,其效力为 0.7-8.5μM,并使用放射性配体竞争结合测定验证了它们的活性。H 受体拮抗作用具有很大的治疗价值,我们的配体可以作为进一步优化先导化合物的起点。这六种配体表现出四种化学支架,其中三种与 ChEMBL 数据库中已知的 H 受体配体相比具有很高的新颖性。完整的药效团片段库可通过 GPCR 数据库 GPCRdb 免费获得,允许在此处成功应用的方法可重复用于 285 个 A 类 GPCR 靶标中的大多数。该方法也可以轻松适应其他蛋白质家族。